Adial Pharmaceuticals 配当と自社株買い
配当金 基準チェック /06
Adial Pharmaceuticals配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-260.4%
バイバック利回り
| 総株主利回り | -260.4% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
Seeking Alpha • Aug 22
Adial Clinical Trial: A Fluff Or A Win?
Onward Phase III Clinical Trial of Adial Pharmaceutical’s AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the primary end-points were not achieved in. Onward trial confirmed estimates of population with the required genetic marker for AD04 treatment, corroborating addressable market and firming up potential value for strategic partners and shareholders. Path forward has two lanes: additional Phase 3 clinical trial focused on Heavy Drinkers and/or application for regulatory approval in Europe. Fluff or Win? Argument for a AD04 win sits on deep foundation of clinical knowledge in ondansetron compound and its effectiveness in treating alcoholism - confirmed by Onward trial. Adial Pharmaceuticals, Inc. (ADIL) has made considerable progress in developing of a therapeutic compound based on ondansetron, a serotonin antagonist, for treatment of alcoholism. The company recently completed a Phase III clinical trial of its AD04 compound involving 302 patients diagnosed with Alcohol Use Disorder ((AUD)), which is characterized by uncontrolled drinking and preoccupation with alcohol. While the overall results of the trial suggested ADO4 treatment demonstrated a beneficial trend, the data was not statistically significant compared to the control group taking a placebo. That said, a predetermined subset of participants receiving AD04 did remarkably well and the subset data was statistically significant. Our earlier article making an investment case for Adial, described how the company is building on successful work using ondansetron as a safe treatment for severe nausea and vomiting. However, Adial’s AD04 compound is aimed at an underserved market populated by about 30 million adults in the U.S. who suffer from AUD. Only about 7% of diagnosed patients actually get treatment. The rest are left floundering around in detoxification and abstinence programs that often do not work. AUD sufferers miss work, lose jobs, fail in school, and engage in conduct that disrupts family and social relationships. The U.S. Centers for Disease Control and Prevention ((CDC)) estimates the economic cost of alcohol abuse and dependence in the workplace alone is as much as $249 billion each year in the U.S. Clearly the economic and social costs are substantial, providing incentive to introduce a new treatment, if an effective one can be found. When the Onward trial results were announced in late July 2022, traders and shareholders immediately registered their disappointment through a dramatic sell-off of ADIL in the first trading session following the results announcement. The shares gave up 47% of value from the previous day close. Since then, the stock has traded down another 15%. By contrast, Adial leadership took encouragement from the trial results for further study and potentially even applications for commercial approval by U.S. and/or European drug regulators. This article considers whether the recent Onward clinical trial was indeed a fluff or actually a resounding win in the ‘effectiveness’ race to a lucrative market. End-point and Beyond It is worthwhile to step back from the headlines to look at ALL the results from the Onward clinical trial. The study was aimed at determining whether AD04 would bring about a reduction in heavy drinking days among trial participants over a period of six months. The trial compared a predetermined baseline with heavy drinking days in month six as well as a combination of months five and six. A few more details on the trial design and execution are included at the end of this article. More importantly, summary of Onward trial results is shown in the illustration right below. Some data points have not yet been disclosed by the company, including specifics related to the puzzling group of Very Heavy Drinkers. Adial leadership has promised those details after the company’s scientists have had a chance to complete the usual analysis needed to plan the next clinical trial or to apply for regulatory approval. Onward Clinical Trial Results (Crystal Equity Research) When the final report comes available, it will be the data related to the Very Heavy Drinkers that will be most interesting - 112 folks who average ten or more drinks per drinking day and represent 37% of the total trial group. Given that the 63% flip side of the study, the Heavy Drinker group, rang in a statistically significant reduction in heavy drinking days from baseline, it is this smaller clutch of participants that appears to have skewed the results for the overall trial. During a conference call in late July 2022, to discuss the Onward study results, Adial leadership pointed to the fact that among the Very Heavy Drinkers, heavy drinking days were reduced by more than 50% in both the AD04 and the placebo group. Reducing heavy drinking days is certainly a desired effect, but regulatory officials, especially those at the U.S. FDA, prefer therapeutic compounds that deliver a statistically significant impact greater than a placebo group. Scientific Foundation This is not the first time the ondansetron compound produced eyebrow raising results. A study completed in 1994 and supported by Glaxo Canada, found a reduction in drinking among alcohol-dependent male participants after six weeks of treatment with ondansetron. Significant differences were found when participants drinking more than 10 drinks per drinking day were excluded from the analysis, leaving only the heavy drinkers. The trial tested two dose levels for the ondansetron - 0.25 mg and 2.0 mg. The lower ondansetron dose produced the greatest reduction from baseline in the heavy drinker group, delivering almost four times the number of participants showing a clinically meaningful decrease in drinking. There is something about the folks drinking ten or more drinks per drinking day! Fortunately, for Adial shareholders, the company’s Chief Medical Officer, Dr. Bankole Johnson, may already have insight into the Very Heavy Drinker group standing out in the Onward trial as well as the similar group in the much earlier trial sponsored by Glaxo Canada. In 2000, Johnson published a paper on yet another randomized controlled trial of ondansetron among biologically disposed alcoholic patients. This study included 271 participants and divided the participants into two groups based on early- or late onset-alcoholism. Early-onset was defined as developing alcoholism at 25 years or younger and those developing alcoholism after age 25 were categorized as late-onset. Among participants with early-onset alcoholism, ondansetron significantly reduced self-reported drinking compared with placebo. However, in the group with late-onset alcoholism only those taking the placebo had significantly improved drinking outcomes. Johnson’s paper postulated that there could be a difference in the condition of the 5-HT3 (serotonin) transporter in patients due to damage by chronic alcohol consumption. The hypothesis at the time was that reduced 5-HT3 neurotransmission in patients with early-onset compared with late-onset alcoholism could impact 5-HT3 receptors. This ‘blockade’ could account for ondansetron’s differential treatment effectiveness among groups with differences in alcoholism severity. The Onward trial appears to echo messages from previous trials, but it will be up to Adial’s scientists to determine if alcoholism severity has any bearing on Onward trial. The message that is important for investors is that Adial scientific team appears well experienced to handle the Onward trial outcome for shareholder benefit. Next Steps on Path to the U.S. FDA and Europe’s EMA During the conference call held following announcement of the Onward trial results and in comments since then, management has remained stalwart in their confidence in AD04 to bring relief to AUD suffers. The Onward trial showed clear benefit for the Heavy Drinker group. There is a pressing need for a safe and palatable treatment in a population that has few options. Plans are already being formulated to approach regulators with the Onward trial results and next steps. One possibility is that the company’s scientists head directly for regulatory approval. At least some preliminary discussion is possible with the EMA (European Medicines Agency) of the European Union that could guide any application for regulatory approval for Europe. Experience in the European market could be beneficial in then clearing the same regulatory hurdle in the U.S. Alternatively, an additional Phase 3 clinical trial could screen for severity of alcohol consumption as well as the genetic marker. Indeed, the company’s scientists are already well prepared for an additional Phase 3 effort, making it possible to begin enrollment even before the end of the current year. AD04 has already shown effectiveness among the Heavy Drinker group of AUD suffers. Thus, a plan for another AD04 trial focused exclusively on that group is likely to be well received by either U.S. or European regulators. The key factor for investors to consider is that while not achieving the planned overall end points, the Onward trial gave Adial scientists a large body of encouraging information to impart to regulators. Most importantly, no information arose that indicated AD04 is in anyway harmful or counter-productive. None of the Onward clinical trial participants with AUD who took AD04 were made worse off. We expect these points of fact to be prominent in Adial leadership’s conversations with regulators. Capital Resources: Cash Kitty and Quest for Partner Of course, next steps require capital. Many investors may have been expecting a regulatory application before the end of the current year. That goal could have been pushed out beyond the current year and may require additional capital. Adial has disclosed that the Onward trial required approximately $12 million investment. An additional clinical trial focused on Heavy Drinkers would likely involve just over 500 participants, potentially requiring between $20 million to $30 million in additional capital. Adial leadership is surprisingly sanguine about capital requirements. The team admits to early conversations with potential strategic partners in AD04, which could contribute new capital to the relationship. Such a partner could also bring a ready-made distribution network, a capability that Adial has never developed. In the meantime, the company has a tidy nest egg to at least begin an additional clinical trial started up or to submit an application for regulatory approval. Adial recently reported financial results for the second quarter, disclosing cash and equivalents totaled $9.2 million at the end of June 2022. The company used approximately $1.0 million per month to support operations during the first six months of 2022. The cash burn rate is likely to remain at this level if the company goes ahead with another clinical trial. Thus, at the current cash usage rate the company can keep the lights on for at least another nine months as well as support additional AD04 development. Addressable Market Confirmed While the Onward trial put a wrinkle in the timeline to regulatory approval, it also provided data to quantify the addressable market for AD04. This is a data point that is critical for investors. The trial confirmed that one third of AUD population has the genetic marker that suggests AD04 could be an effective treatment. The number of potential patients is remarkable.Seeking Alpha • Aug 16
Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01
Adial Pharmaceuticals press release (NASDAQ:ADIL): Q2 GAAP EPS of -$0.16 beats by $0.01. As of June 30,2022, cash and cash equivalents were $9.2 million as compared to $6.1 million as of December 31, 2021, which the Company believes provides sufficient runway to advance ongoing regulatory and partnering activities related to AD04, as well as advancement of its Purnovate platform. Shares +5% PM.Seeking Alpha • Jun 21
Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst
I last reported on Adial 8 months ago - the micro-cap is developing a micro-formulation of Ondansetron - a treatment for nausea and sickness - to treat alcohol use disorder. A 24-week Phase 3 trial is underway in Europe and Scandinavia with an endpoint of reduction in Heavy Drinking Days and total alcohol consumption. Adial is targeting approval in Europe and the US - where it has submitted for Fast Track status. Europe looks a likelier approval shot owing to FDA's stricter trial endpoint. The company's market cap is just $51m and share count 18m. Shareholder dilution is likely - to secure funds for trials and marketing, if approved - as is an acquisition. I still see significant upside potential with Adial and its AUD treatment AD04, based on the EMA approval catalyst, which may arrive next year, but there are a lot of risks and imponderables.決済の安定と成長
配当データの取得
安定した配当: ADILの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: ADILの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Adial Pharmaceuticals 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (ADIL) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.3% |
| 業界平均 (Pharmaceuticals) | 2.1% |
| アナリスト予想 (ADIL) (最長3年) | n/a |
注目すべき配当: ADILは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: ADILは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: ADILの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: ADILが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 15:06 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Adial Pharmaceuticals, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Theodore O'Neill | Litchfield Hills Research, LLC |
| Jason McCarthy | Maxim Group |